Skip to main content

Table 2 Main outcome table. Baseline Montgomery Åsberg Depression Rating Scale (MADRS) scores and change in the depressive symptoms over 52 weeks for patients in the intention-to-treat and per-protocol analysis. Values are means unless stated otherwise. Estimated mean differences and 95% Confidence Intervals (CIs) are presented.

From: Clinical effectiveness of usual care with or without antidepressant medication for primary care patients with minor or mild-major depression: a randomized equivalence trial

  Intention-to-treat MADRS (n = 181)
  Usual care + paroxetine (n = 85) Usual care (n = 96) Mean difference* SD 95% CI
Baseline score 23.7 24.1    
6 weeks – baseline† -7.6 -6.0 -1.6 20.2 -4.7; 1.4‡
13 weeks – baseline † -10.2 -8.7 -1.5 22.5 -5.1; 1.9
26 weeks – baseline † -13.0 -10.0 -3.0 21.3 -6.4; 0.3
52 weeks – baseline † -14.7 -12.6 -2.1 24.1 -6.1; 1.9
  Per-protocol MADRS (n = 133)
  Usual care + paroxetine (n = 55) Usual care (n = 78) Mean difference* SD 95% CI
Baseline score 25.1 24.1    
6 weeks-baseline† -7.8 -6.7 -1.1 20.0 -4.5; 2.4‡
13 weeks-baseline† -12.1 -9.0 -3.1 20.7 -6.8; 0.5
26 weeks-baseline† -13.9 -9.3 -4.6 20.6 -8.4; -0.9§
52 weeks-baseline† -17.6 -12.6 -5.0 21.2 -9.1; -1.0§
  1. *A negative mean difference is a difference in favor of usual care + paroxetine.
  2. †A negative score means a decrease in the severity of symptoms.
  3. ‡The 95% CI of the difference in symptom change lies entirely between the equivalence margins of -5 and +5 points, indicating equivalence of usual care + paroxetine and usual care.
  4. §The 95% CI of the difference in symptom change lies entirely to the left of zero, indicating statistical significant differences in favor of usual care + paroxetine.